Premium
P2–407: Effects of ibuprofen on Alzheimer's disease cognitive progression: A randomized controlled trial
Author(s) -
Zanetti Orazio,
Bonomini Cristina,
Pasqualetti Patrizio,
Milazzo Daniele,
Paulon Luca,
Dal Forno Gloria,
Sinforiani Elena,
Marra Camillo,
Cassetta Emanuele,
Carnaghi Roberto,
Peresson Marco,
Pauri Flavia,
Rossini Paolo M.
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.1248
Subject(s) - placebo , medicine , ibuprofen , randomized controlled trial , gastroenterology , alzheimer's disease , disease , pharmacology , pathology , alternative medicine
(Alzheimer’s Disease Assessment Scale cognitive subscale, or Severe Impairment Battery; ADAS-cog or SIB), and function (Alzheimer’s Disease Cooperative Study Activities of Daily Living 19or 23-item scale; ADCS-ADL19/23) were investigated. Safety was analysed via the incidence rates of adverse events. Results: Memantine was statistically significantly superior to placebo in all three efficacy domains. Standardized mean differences between memantine and placebo were as follows (OC analysis) global status (0.22; p 0.001), cognition (0.26; p 0.001), and function (0.18; p 0.001). LOCF analysis showed similar results. The analysis of AE rates confirmed that memantine is safe and well tolerated, with an overall incidence of adverse events that was comparable to placebo. Conclusions: In patients with moderate to severe AD, memantine offers significant benefits over placebo in the three clinically most relevant domains of global status, cognition, and function. The current meta-analysis supports the use of memantine across this range of disease stages, highlighting a clinically relevant efficacy and favourable safety profile.